Hellum Christian, Rekeland Frode, Småstuen Milada Cvancarova, Solberg Tore, Hermansen Erland, Storheim Kjersti, Brox Jens Ivar, Furunes Håvard, Franssen Eric, Weber Clemens, Brisby Helena, Grundnes Oliver, Algaard Knut Robert Hector, Böker Tordis, Banitalebi Hasan, Indrekvam Kari, Austevoll Ivar Magne
Division of Orthopedic Surgery, Oslo University Hospital Ullevål, Fallanveien 6c, Oslo, Norway.
Kysthospitalet in Hagevik, Orthopedic Department, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Spine J. 2023 Nov;23(11):1613-1622. doi: 10.1016/j.spinee.2023.06.386. Epub 2023 Jun 22.
Patients with spinal stenosis and degenerative spondylolisthesis are treated surgically with decompression alone or decompression with fusion. However, there is debate regarding which subgroups of patients may benefit from additional fusion.
To investigate possible treatment effect modifiers and prognostic variables among patients operated for spinal stenosis and degenerative spondylolisthesis.
A secondary exploratory study using data from the Norwegian Degenerative Spondylolisthesis and Spinal Stenosis (NORDSTEN-DS) trial. Patients were randomized to decompression alone or decompression with instrumented fusion.
The sample in this study consists of 267 patients from a randomized multicenter trial involving 16 hospitals in Norway. Patients were enrolled from February 12, 2014, to December 18, 2017. The study did not include patients with degenerative scoliosis, severe foraminal stenosis, multilevel spondylolisthesis, or previous surgery.
The primary outcome was an improvement of ≥ 30% on the Oswestry Disability Index score (ODI) from baseline to 2-year follow-up.
When investigating possible variables that could modify the treatment effect, we analyzed the treatment arms separately. When testing for prognostic factors we analyzed the whole cohort (both treatment groups). We used univariate and multiple regression analyses. The selection of variables was done a priori, according to the published trial protocol.
Of the 267 patients included in the trial (183 female [67%]; mean [SD] age, 66 [7.6] years), complete baseline data for the variables required for the present analysis were available for 205 of the 267 individuals. We did not find any clinical or radiological variables at baseline that modified the treatment effect. Thus, none of the commonly used criteria for selecting patients for fusion surgery influenced the chosen primary outcome in the two treatment arms. For the whole cohort, less comorbidity (American Society of Anesthesiologists Classification [ASA], OR = 4.35; 95% confidence interval (CI [1.16-16.67]) and more preoperative leg pain (OR = 1.23; CI [1.02-1.50]) were significantly associated with an improved primary outcome.
In this study on patients with degenerative spondylolisthesis, neither previously defined instability criteria nor other pre-specified baseline variables were associated with better clinical outcome if fusion surgery was performed. None of the analyzed variables can be applied to guide the decision for fusion surgery in patients with degenerative spondylolisthesis. For both treatment groups, less comorbidity and more leg pain were associated with improved outcome 2 years after surgery.
NORDSTEN-DS ClinicalTrials.gov, NCT02051374.
患有椎管狭窄和退行性椎体滑脱的患者可通过单纯减压手术或减压融合手术进行治疗。然而,关于哪些亚组患者可能从额外的融合手术中获益仍存在争议。
研究接受椎管狭窄和退行性椎体滑脱手术患者中可能的治疗效果调节因素和预后变量。
一项二次探索性研究,使用来自挪威退行性椎体滑脱和椎管狭窄(NORDSTEN-DS)试验的数据。患者被随机分为单纯减压组或器械辅助融合减压组。
本研究的样本包括来自挪威16家医院的一项随机多中心试验中的267名患者。患者于2014年2月12日至2017年12月18日入组。该研究不包括患有退行性脊柱侧凸、严重椎间孔狭窄、多节段椎体滑脱或既往手术史的患者。
主要结局是从基线到2年随访时,奥斯威斯功能障碍指数(ODI)评分改善≥30%。
在研究可能改变治疗效果的变量时,我们分别分析了治疗组。在测试预后因素时,我们分析了整个队列(两个治疗组)。我们使用了单变量和多变量回归分析。变量的选择是根据已发表的试验方案预先确定的。
在纳入试验的267名患者中(183名女性[67%];平均[标准差]年龄,66[7.6]岁),267名个体中有205名可获得本分析所需变量的完整基线数据。我们在基线时未发现任何临床或放射学变量可改变治疗效果。因此,在两个治疗组中,用于选择融合手术患者的常用标准均未影响所选的主要结局。对于整个队列,合并症较少(美国麻醉医师协会分级[ASA],比值比[OR]=4.35;95%置信区间[CI][1.16-16.67])和术前腿痛较多(OR=1.23;CI[1.02-1.50])与主要结局改善显著相关。
在这项关于退行性椎体滑脱患者的研究中,如果进行融合手术,先前定义的不稳定标准或其他预先指定的基线变量均与更好的临床结局无关。所分析的变量均不能用于指导退行性椎体滑脱患者的融合手术决策。对于两个治疗组,合并症较少和腿痛较多与术后2年结局改善相关。
NORDSTEN-DS,ClinicalTrials.gov,NCT02051374。